The cancer therapy developer and Jackson Laboratory spinout floated at the upper end of its range and now has a $600m market cap.

Cyteir Therapeutics, a US-based oncology therapeutics developer spun out of non-profit research hub Jackson Laboratory, floated on Friday in a $133m initial public offering on the Nasdaq Global Select Market.
The company priced 7.4 million shares at $18 each, at the upper end of the $16 to $18 range it had initially set. Its shares closed on $17.40 on its first day of trading, indicating a market capitalisation of approximately $600m.
Founded in 2012, Cyteir is developing small…